Curious to see the emissions of the organizations you buy from or invest in?
Book a demo for a pilot project
Book a demo for a pilot project
Eisai Co., Ltd., a prominent player in the pharmaceutical preparation manufacturing industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and North America. Founded in 1941, Eisai has established itself as a leader in the development of innovative treatments, particularly in neurology and oncology, with a commitment to addressing unmet medical needs.
The company is renowned for its core products, including the Alzheimer's treatment Aricept and the anti-cancer agent Lenvima, both of which exemplify Eisai's dedication to research and development. With a strong market position, Eisai has achieved significant milestones, including numerous collaborations and partnerships that enhance its global reach and impact. Through its focus on patient-centric solutions, Eisai continues to make strides in improving health outcomes worldwide.
+27 vs industry average
Eisai’s score of 69 is higher than 74% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Pharmaceutical Preparation Manufacturing has above-average carbon intensity
The Pharmaceutical Preparation Manufacturing industry has increased its overall emissions by 132% since 0
Scope 3 accounts for ••• of total emissions.
Eisai, a Pharmaceutical Preparation Manufacturing company based in Japan, reported its latest available emissions data for 2024. In 2024, the company's Scope 1 emissions were 45,666,000 kg CO2e, and Scope 2 market-based emissions were 3,921,000 kg CO2e. Scope 3 emissions, specifically from purchased goods and services, amounted to 825,382,000 kg CO2e.
Eisai has set ambitious climate commitments. The company aims to achieve Net-Zero emissions by 2050. For near-term targets, Eisai commits to reducing its absolute Scope 1 and 2 GHG emissions by 55% by fiscal year 2030, from a fiscal year 2019 base year. Additionally, it plans to reduce its Scope 3 GHG emissions from purchased goods and services by 27.5% within the same timeframe. These targets align with the Science Based Targets initiative (SBTi) 1.5°C warming scenario.
2030
55% reduction in Scope 2
Eisai Co., Ltd. commits to reduce absolute scope 1 and 2 GHG emissions 55% by FY2030 from a FY2019 base year. Eisai Co., Ltd. also commits t…
2030
55% reduction in Scope 1
Eisai Co., Ltd. commits to reduce absolute scope 1 and 2 GHG emissions 55% by FY2030 from a FY2019 base year. Eisai Co., Ltd. also commits t…
Showing SBTi-validated targets only. Sign up or sign in to see all disclosed climate targets.
See all scope 3 categories
Already have an account? Sign in now


PCAF scored Scope 1, 2 and 3 for 2M+ organizations, including private ones.
Common questions about Eisai’s sustainability data and climate commitments
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn more